Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SELECT: Omitting Chemotherapy in ER+/HER2- Breast Cancer with Ribociclib and Endocrine Therapy
NCT06953882Phase 2Recruiting
- Sponsor
- Yale University
- Start
- Jul 2025
- Primary completion
- Sep 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ribociclib in breast cancer (2 arms), sponsored by Yale University. Primary endpoint: Discontinuation rate of ribociclib at 1 year. Started Jul 2025; status: recruiting.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06953882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06953882.